业绩简评 2025 年 4 月 27 日公司披露 24 年报，24 年实现营收 12.22 亿元， 同比增长 20.98%，市场份额稳居本土 EDA 企业首位；归母净利润 1.09 亿元，同比下降 45.46%；扣非归母净利润亏损 0.57 亿元。 单 Q4 公司实现营收 4.79 亿元，同比增长 29.13%；实现归母净利 润 0.51 亿元，同比增长 73.71%。 分业务来看，24 年公司 EDA 软件销售营收为 10.92 亿元，同比增 长 20.71%；技术服务业务营收为 1.15 亿元，同比增长 40.01%； 硬件、代理软件销售及其他收入 0.15 亿元，同比下降 35.71%。公 司境外收入占比为 4.72%，收入同比下降 13.32%。 成本费用方面，24 年公司毛利率为 93.31%，较上年同期下降 0.48pct。公司剔除股份支付费用后的销售/管理/研发费用率分别 为 16.31%/12.05%/60.79% ， 分 别 同 比 下 降 0.03pct/0.57pct/6.61pct。截至 24 年末公司共有员工 1,202 人， 同比增加 17.50%，其中销售/技术人员同比增长 17 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenue reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is projected to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenues reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is forecasted to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [4][9] Core Views - The company experienced short-term performance pressure but is actively expanding its overseas market, which is expected to create new growth points in the electric meter and energy storage businesses [2][3] - In 2024, the company achieved an operating income of 6.742 billion RMB, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 753 million RMB, down 27% year-on-year [2][8] - The overseas revenue reached 1.126 billion RMB in 2024, marking a 34% year-on-year increase, indicating successful market expansion efforts [3] Summary by Sections Performance Overview - In 2024, the company reported an operating income of 6.742 billion RMB, a decrease of 1.89% from the previous year, and a net profit of 753 million RMB, down 27% year-on-year [2][8] - The first quarter of 2025 saw an operating income of 1.124 billion RMB, a 27% decline year-on-year, with a net profit of 124 million RMB, down 43% [2] Business Analysis - The company is focusing on overseas market expansion, with a significant partnership with global meter leader Landis+Gyr to increase market share in Western Europe and Asia-Pacific [3] - The energy storage segment generated 920 million RMB in revenue in 2024, a 39% decline, but maintained a gross margin of 17.64%, an increase of 1.55 percentage points year-on-year [3] - The company’s power station construction is progressing steadily, with power station revenue of 1.19 billion RMB in 2024, down 8%, but with a gross margin of 25.94%, up 14.46 percentage points year-on-year [3] Profit Forecast and Valuation - The projected net profits for 2025, 2026, and 2027 are 850 million RMB, 970 million RMB, and 1.1 billion RMB, respectively, with corresponding price-to-earnings ratios of 15, 13, and 12 times [4][8]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company reported a revenue of 831 million RMB for 2024, a decrease of 1.77% year-on-year, and a net profit attributable to shareholders of 144 million RMB, down 36.89% year-on-year. For Q1 2025, revenue was 239 million RMB, an increase of 8.85%, while net profit was 31 million RMB, down 26.99% year-on-year [2] - The company is experiencing a gradual recovery in operations, with revenue growth turning positive in Q4 2024 and Q1 2025. The company is strengthening its position in the outdoor equipment manufacturing sector while increasing investment in new product development [3] - The company is expanding its international market presence, having established partnerships with new brand clients in Australia and North America, with some products already in mass production [3] Summary by Sections Performance Review - For 2024, the company expects to distribute cash dividends of 67.53 million RMB, with a dividend payout ratio of approximately 52% [2] Operational Analysis - Revenue from tents, sleeping bags, clothing, and backpacks for 2024 was 361 million, 117 million, 256 million, and 39 million RMB respectively, with year-on-year changes of -22.33%, -2.29%, +41.73%, and -4.61% [3] - The company aims to deepen customer relationships and expand its high-potential customer base while introducing high-performance materials into its product lines [4] Financial Forecast and Valuation - The company is projected to have EPS of 2.36, 2.60, and 2.88 RMB for 2025-2027, corresponding to PE ratios of 15, 14, and 12 times [5] - The company’s revenue is expected to grow to 936 million RMB in 2025, with a growth rate of 12.68% [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Insights - The company reported a revenue of 26.497 billion RMB in 2024, reflecting an 8.0% year-on-year growth, while the net profit attributable to shareholders decreased by 21.6% to 915 million RMB [2]. - In Q1 2025, the company achieved a revenue of 6.956 billion RMB, a 3.0% increase year-on-year, with a net profit of 460 million RMB, up 15.5% year-on-year [2]. - The company is in a period of adjustment, optimizing its store network, which is expected to lead to stable profit growth post-adjustment [3]. Summary by Sections Performance Review - In 2024, the company achieved a total revenue of 26.497 billion RMB, with a net profit of 915 million RMB, and a non-recurring net profit of 885 million RMB, both showing declines compared to the previous year [2]. - For Q1 2025, the company reported a revenue of 6.956 billion RMB and a net profit of 460 million RMB, indicating a positive trend in profitability [2]. Operational Analysis - The company opened 907 self-built stores, acquired 420 stores, and added 1,885 franchise stores in 2024, while closing 733 stores to optimize its network [3]. - In Q1 2025, the company added 69 stores, including 54 new openings and 189 franchise stores, while closing 174 stores, resulting in a total of 16,622 stores [3]. - The fastest-growing segment in Q1 2025 was the Chinese and Western medicine category, generating approximately 5.32 billion RMB in revenue, a 5.8% increase year-on-year [3]. Profit Forecast, Valuation, and Rating - The company is expected to gradually return to normal growth after the adjustment period, with projected net profits of 1.1 billion RMB, 1.32 billion RMB, and 1.52 billion RMB for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 20.1%, 19.8%, and 15.3% [3]. - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are 0.96 RMB, 1.16 RMB, and 1.33 RMB, with corresponding price-to-earnings (P/E) ratios of 17, 15, and 13 times [3].

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 458 million, 598 million, and 759 million RMB, representing year-on-year growth of 34%, 30%, and 27% respectively, corresponding to PE ratios of 36, 28, and 22 times [3][8]. Core Insights - The company's gross margin improved to 76.05% in Q1 2025, with a year-on-year increase of 1.44 percentage points and a quarter-on-quarter increase of 4.13 percentage points. The sales expense ratio decreased by 3.24 percentage points quarter-on-quarter to 52.17%, while the management expense ratio and R&D expense ratio saw slight reductions [3][8]. - The main brand, Marubi, continues to strengthen its market position in "eye care and wrinkle reduction," with a revenue of 2.055 billion RMB in 2024, a year-on-year increase of 31.69%, accounting for 69.24% of total revenue. The brand's flagship products have shown significant online sales growth [9][8]. - The PL brand, focusing on the base makeup segment, achieved a revenue of 905 million RMB in 2024, a year-on-year increase of 40.72%, contributing 30.51% to total revenue. Six foundation products exceeded 100 million RMB in annual GMV, indicating strong product performance [9][8]. Summary by Sections Financial Performance - The company reported a revenue of 2.226 billion RMB in 2023, with a growth rate of 28.52%. The projected revenue for 2024 is 2.970 billion RMB, with a growth rate of 33.44%. The net profit attributable to the parent company is expected to reach 342 million RMB in 2024, reflecting a growth rate of 31.69% [7][8]. - The diluted earnings per share are projected to increase from 0.647 RMB in 2023 to 1.143 RMB in 2025, with a corresponding increase in return on equity (ROE) from 7.75% in 2023 to 12.86% in 2025 [7][8]. Market Position - The report highlights the competitive landscape, noting that the main brand's growth has not met expectations due to intense online competition and slower-than-expected recovery in offline sales. However, the ongoing optimization of product structure and the deepening of the single product strategy are expected to drive future growth [3][8].

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 458 million, 598 million, and 759 million RMB, representing year-on-year growth of 34%, 30%, and 27% respectively, corresponding to P/E ratios of 36, 28, and 22 times [3][8]. Core Insights - The company's gross margin improved to 76.05% in Q1 2025, with a year-on-year increase of 1.44 percentage points and a quarter-on-quarter increase of 4.13 percentage points. The sales expense ratio decreased by 3.24 percentage points quarter-on-quarter to 52.17%, while the management expense ratio and R&D expense ratio saw slight reductions [3][8]. - The main brand, Marubi, continues to strengthen its market position in "eye care and wrinkle reduction," with a revenue of 2.055 billion RMB in 2024, a year-on-year increase of 31.69%, accounting for 69.24% of total revenue. The brand's flagship products have shown significant online sales growth [9][8]. - The PL brand, focusing on the mass foundation market, achieved a revenue of 905 million RMB in 2024, a year-on-year increase of 40.72%, contributing 30.51% to total revenue. Six foundation products exceeded 100 million RMB in annual GMV, showcasing strong product performance [9][8]. Summary by Sections Financial Performance - The company reported a revenue of 2.226 billion RMB in 2023, with a growth rate of 28.52%. The projected revenues for 2024 and 2025 are 2.970 billion and 3.856 billion RMB, with growth rates of 33.44% and 29.85% respectively [7][11]. - The net profit attributable to the parent company for 2023 is 259 million RMB, with projections of 342 million and 458 million RMB for 2024 and 2025, reflecting growth rates of 48.93% and 31.69% [7][11]. Market Position and Strategy - The company is deepening its focus on major product strategies and online transformation, with both Marubi and PL brands showing strong momentum. The online and offline revenue for 2024 is projected at 2.541 billion and 427 million RMB, with year-on-year growth of 35.77% and 20.79% respectively [9][8]. - The report highlights the competitive landscape, noting that the main brand's growth has not met expectations due to intense online competition and slower-than-expected offline recovery [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Views - The company reported a revenue of 26.497 billion RMB in 2024, an increase of 8.0% year-on-year, but a decline in net profit attributable to shareholders by 21.6% to 915 million RMB [2]. - In Q1 2025, the company achieved a revenue of 6.956 billion RMB, a 3.0% increase year-on-year, with a net profit of 460 million RMB, reflecting a 15.5% increase [2]. - The company is undergoing a period of adjustment, optimizing its store network, which is expected to lead to stable profit growth post-adjustment [3]. Summary by Sections Performance Review - In 2024, the company achieved a total revenue of 26.497 billion RMB, with a net profit of 915 million RMB, and a non-recurring net profit of 885 million RMB, both showing declines compared to the previous year [2]. - For Q1 2025, the company reported a revenue of 6.956 billion RMB and a net profit of 460 million RMB, indicating positive growth in profitability [2]. Operational Analysis - The company opened 907 self-built stores, acquired 420 stores, and added 1,885 franchise stores in 2024, while closing 733 stores to optimize its network [3]. - In Q1 2025, the company net added 69 stores, with 54 new openings and 189 franchise additions, while closing 174 stores [3]. - The fastest-growing segment in Q1 2025 was traditional Chinese and Western medicine, generating approximately 5.32 billion RMB in revenue, a 5.8% increase year-on-year [3]. Profit Forecast, Valuation, and Rating - The company is expected to gradually return to normal growth after the adjustment period, with projected net profits of 1.1 billion RMB, 1.32 billion RMB, and 1.52 billion RMB for 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 20.1%, 19.8%, and 15.3% [3]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.96 RMB, 1.16 RMB, and 1.33 RMB, with corresponding price-to-earnings (P/E) ratios of 17, 15, and 13 times [3].

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 16.69 billion, 19.14 billion, and 21.84 billion RMB respectively, reflecting growth rates of +26%, +15%, and +14% [5] Core Insights - The company's Q1 2025 performance showed a revenue of 3.794 billion RMB, up 8.95% year-on-year, and a net profit attributable to shareholders of 370 million RMB, up 16.02% year-on-year, indicating that the performance met expectations [2] - The main business continues to grow steadily, with the sugar business being gradually divested. Yeast and deep processing products generated 2.773 billion RMB in revenue, a 13.2% increase year-on-year, while the sugar segment saw a significant decline in revenue by 60.7% [3] - Cost reductions have led to improved net profit margins, with a net margin of 9.75%, up 0.59 percentage points year-on-year, driven by a decrease in raw material costs and better product mix [4] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 3.794 billion RMB, with a year-on-year growth of 8.95%, and a net profit of 370 million RMB, reflecting a 16.02% increase [2] - The company’s gross margin improved to 25.97%, up 1.31 percentage points year-on-year, due to lower procurement costs and increased efficiency [4] Business Segments - The yeast and deep processing segment generated 2.773 billion RMB in revenue, up 13.2% year-on-year, while the sugar segment's revenue fell by 60.7% to 1.57 billion RMB [3] - Domestic revenue slightly decreased by 0.3% to 2.099 billion RMB, while international revenue increased by 22.9% to 1.684 billion RMB, indicating strong overseas market growth [3] Future Projections - The company expects net profits to grow significantly over the next few years, with projections of 16.69 billion RMB in 2025, 19.14 billion RMB in 2026, and 21.84 billion RMB in 2027, corresponding to PE ratios of 18x, 15x, and 13x respectively [5]